http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019002571-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72192b485edb2254e5fa13f023bd4de4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
filingDate 2016-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0a3df28c5c3976106be2a6bfc1ba7d6
publicationDate 2019-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2019002571-A1
titleOfInvention Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions
abstract Methods for the therapeutic use of competitive inhibitors of the CCR5/CCL5 axis that express antagonist activity for RANTES (CCL5) for immunomodulatory treatment of subjects in need thereof. The competitive inhibitors may not have CCL5 agonist activity and can be used to inhibit, interrupt, block, mitigate, slow the progress of, and/or treat inflammation and/or various other CCR5/CCL5 axis signaling dependent down-stream activities associated with transplantation, including graft versus host disease, autoimmune disorders, infectious agents, chronic inflammation, and cancer, etc.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020243371-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11045546-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021146323-A1
priorityDate 2015-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005016226-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014085808-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014377259-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394054
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394037
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12068910
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73073
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6076
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25322948
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397217
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14389199
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID47936
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3002977
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3009355
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6083
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226501542
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226490736
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5092
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421630
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226435168
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411130
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57473858
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226502262
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226502261
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396823
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415393

Total number of triples: 48.